- Home
- OTLK vs IMRX Comparison
OTLK vs IMRX Comparison
Compare OTLK & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- IMRX
- Stock Information
- Founded
- OTLK 2010
- IMRX 2008
- Country
- OTLK United States
- IMRX United States
- Employees
- OTLK N/A
- IMRX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- IMRX Health Care
- Exchange
- OTLK Nasdaq
- IMRX Nasdaq
- Market Cap
- OTLK 56.3M
- IMRX 62.7M
- IPO Year
- OTLK 2016
- IMRX 2021
- Fundamental
- Price
- OTLK $1.48
- IMRX $1.56
- Analyst Decision
- OTLK Strong Buy
- IMRX Buy
- Analyst Count
- OTLK 5
- IMRX 6
- Target Price
- OTLK $10.20
- IMRX $9.00
- AVG Volume (30 Days)
- OTLK 479.6K
- IMRX 220.6K
- Earning Date
- OTLK 02-14-2025
- IMRX 05-06-2025
- Dividend Yield
- OTLK N/A
- IMRX N/A
- EPS Growth
- OTLK N/A
- IMRX N/A
- EPS
- OTLK N/A
- IMRX N/A
- Revenue
- OTLK N/A
- IMRX N/A
- Revenue This Year
- OTLK N/A
- IMRX N/A
- Revenue Next Year
- OTLK $288.46
- IMRX N/A
- P/E Ratio
- OTLK N/A
- IMRX N/A
- Revenue Growth
- OTLK N/A
- IMRX N/A
- 52 Week Low
- OTLK $0.87
- IMRX $1.00
- 52 Week High
- OTLK $12.85
- IMRX $6.00
- Technical
- Relative Strength Index (RSI)
- OTLK 40.05
- IMRX 35.81
- Support Level
- OTLK $1.38
- IMRX $1.42
- Resistance Level
- OTLK $1.51
- IMRX $1.58
- Average True Range (ATR)
- OTLK 0.12
- IMRX 0.10
- MACD
- OTLK 0.02
- IMRX -0.00
- Stochastic Oscillator
- OTLK 38.86
- IMRX 28.57
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.